Marka loo eego natiijooyinka 5-sano ee dabagalka ah ee tijaabada PACE ee muhiimka ah ee lagu daabacay Joornaalka Hematology, panatinib (Ponatinib, Iclusig) waxay muddo dheer ku sii jirtey bukaanada sida xun loola dhaqmay ee leh marxaladda daba dheeraatay ee myeloid leukemia chronic (CP-CML) falcelin.
Iskucelcelis dabagal ah 56.8 bilood, 60% (n = 159) oo ka mid ah 267 bukaanno la qiimeyn karo ah ayaa ku guuleystay jawaab celis weyn (MCyR). 54% (n = 144) bukaanada waxay heleen jawaab celis dhameystiran. 40% (n = 108) patients achieved a major molecular response (MMR), and 24% (n = 64) achieved a molecular response. During the median follow-up period, at 12 months, 82% of patients achieved MCyR, and at 5 years, an estimated 59% of patients achieved MMR. The most common (≥40%) adverse events (TEAE) were rash (47%), abdominal pain (46%), thrombocytopenia (46%), headache (43%), dry skin (42%) and constipation (41%).
In the entire 270 patient cohort, more than 90% of patients had received at least 2 TKI treatments. Investigators found that the response was related to long-term results. The 5-year progression-free survival (PFS) is expected to be 53%, and the overall survival (OS) is 73%.
Sii deynta xogtan waa guul muhiim ah maxaa yeelay waxay muujineysaa in Ponatinib ay wali tahay ikhtiyaar daaweyn wax ku ool ah oo loogu talagalay bukaanada ku habboon ee horay u fashilmay TKI (oo ay ku jiraan bukaannada qaba T315I mutation).
